heimlich institute's 1992 "immunotherapy for aids" fundraising prospectus

8/13/2019 Heimlich Institute's 1992 "Immunotherapy for AIDS" fundraising prospectus

1/13

IMT: A POTENTIALCURE FOR AIDS

A Proposal For Funding

Submitted byThe Heimlich Institute Foundation, Inc.

2368 Victory Parkway Suite 410Cincinnati, Ohio 45206

(513)221-0003


2/13

Confidentiality StatementiGiven the wide public recognition ofDr.Heimiich, any release of informationconcerning his involvement in this project would result in an avalanche of interestwhich we wish to avoid until IMT is clinically validated. We also request that thereader maintain the strictest confidentiality concerning this proposal and the

identities of mem bers ofmeproject team .The Aids Epidemic

AIDS is one of the most tragic problems to confront contemporary society.According to Reuters World News Highlights (September 13,1992), over6 000 000people have been infected withHTVin Africa alone, and over 800,000Africans currently have AIDS and are expected to die from it.The number of Africans infected is expected to reach 15,000,000 by the end of theyear. A similar epidemic is underway in India, and in fact, AIDS has become adevastating problem throughout the w orld.According to a 99 report published by the A gency for Health Care Policy andResearch of the U .S. Dept. of Health and Human Services, the cost in 1991 oftreating Americans infected withHTVis $5.8 billion and it is forecast thatthiswillincrease21%each year between 1991 and 1994 when $10.4 billion will be spent.The costs in terms of human suffering is incalculable, and yet, despite additionalbillions of dollars spent in laboratory research, no definitive cure has appearedeven on the horizon,

IMT and AIDSDr. Heimiich has never been convinced that drags will cure AIDS, since there is noknown drug cure for anv viral disease, including the common cold. In addition,Albert Sabin, the renown polio researcher, stated in a recent news report(September 16,1992) that any effort to prevent the spread of AIDS through avaccine is doomed.HIV (or whatever unknown substance that causes AIDS) kills by destroying thebody's production of immune substances, enabling secondary lethal infections togo unchecked. The answertocuring AIDS is to stimulate the HIV-positivepatient's immune system to produce immune substances that are capable ofdestroying theHTVvirus.

IMT and AIDS Privilegedan d onfidential Page


3/13

The technique of deliberately giving a disease to cure or prevent another disease iswell kno wn in the history of medicine. Exam ples include cowpox vaccination toprevent sm allpox, and Sabin live polio vaccine to prev ent polio.IMT (Induced M alaria Therapy) consists of inoculating a patient with a curableform of malaria (usually Plasmodium vivax l to cure another disease that isotherwise incu rable. It was pioneered by Wagner-Jauregg who was awarded theNobel Prize in 1927 for his discovery that IMT cured neurosyphilis (syphilis of thebrain).Research s tudies cond ucted at UC Berkeley, W alter Reed A rmy Institute ofResearch, and He idelberg University, independently dem onstrated that malariainduces production of various imm une substances, including interleukins andtumor necrosis factor.These reports stimulated Dr. Heimlich's interest in the possible use of IMT forAIDS patients and, in a continuing search of the


4/13

The AIDS Treatment ProjectW e propose to trea t 10 HTV positive patient volu nteers utilizing IM T. Subjectsaccepted for IMT treatment will travel to our Txas facility for further evaluationsand preliminary laboratory studies, and then to ou r nearby M exican facility whereIMT will be administered.We have had an active IMT program in Mexico City for treating Americans andother Lyme disease and cancer patients for several years. Recen tly, we haveestablished an additional clinic in a Mexican city a few minutes from a city inTexas specifically to conduct IM T for AIDS patients .Our M exican team has on hand the benign form of malaria, and we are ready toproceed with the treatment of AIDS patients pending funding.Th e metho ds of treatment we will use are well established from the m ore than 60years that IM T has been used. Our team has Mso gained experience fromsuccessfully treating Lyme disease and cancer patients in Mexico and China duringthe past five years.Each HTV positive patient will receive an inoculation containing malaria parasites.M alaria fever typica lly occurs every other day. On the first day fever oc curs, thepatient will be adm itted to the me dical facility. After 10 to 14 fevers (20 to 28days), antimalarial m edications w ill be adm inistered. In all the years that IM T hasbeen utilized , there is not a single report of a failure to cu re this deliberatelyinduced malaria.After the second day of antimalarial treatment, the patient will be permitted toreturn home to Los A ngeles. They will be followed closely and periodically re-evaluated by members of our Los Angeles team.

ConclusionGiven our successful experience in utilizing IMT for Lyme disease and cancer, webelieve that IMT represents a highly promising cure for AID S. W e expect that theHIV vims will be destroyed by the enhanced im mu nity induced by IM T, and thatthe patients will be cured.It is our hope that this project can be completed before the end of 1993, and thatthe AID S scourge w ill soon be ended. You r active support of this work is m ostappreciated.

IMT and AIDS Privileged and Confidential -Page 4


5/13

Project Staff MembersH en ry J. Heim lich M.D. Principal Investigator, has been credited with savingmore lives than any other living perso n. Tens of thou san ds of lives have beensaved by the H eimlich M aneuver, and he is also well know n for his many otherscientific accom plishmen ts, including the Heim lich Op eration, The HeimlichMicro Trach, and the Heimlich Chest Drain Va lve. He has received num erousawards, honorary degrees, and commendations including the Albert LaskerAwara\ the American Academy of Achievement Golden Plate Award, andenshrinement in the Engineering and Science Hall of Fame.David E. Bresler Ph.D. L.Ac.. Clinical Director, is the co-director of the CenturyCity Hosp ital Pain Control Center in Los A nge les, the former Director of theUCLA Pain Control Unit and former Adj. Asst. Professor of Anethesiology,Gnathology and Occlusion, and Psychology in the UCLA Schools of Medicine,Dentistry, and the UCL A College of Letters and Sc ien ces . He has been a pioneerin cond ucting scientific research regarding the Clinical effectiveness of acupunctureand guided imagery, and has authored over 100 scientific articles and books.E d w a r d A .Patrick M.D. P h.D. FACEP, Medical Director, Heimlich Institute.Before becoming a medical doctor, Dr. Patrick received a B.S. and M.S. inElectrical Engin eering at M .I.T. He went on to receiv e his Ph .D. from PurdueUniv ersity. After completing his M .D. at Indian a Univ ersity Scho ol of Medicine in1974, Dr. Patrick (tenured professor of Electrical Engineering at PurdueUniversity) specialized in eme rgency m edic ine. Dr . Patrick is a board certifiedEm ergency Med ical Physician, and a Fellow of the Am erican C ollege ofEm ergency Ph ysicians. As past President of I.E.E.E. System, M an andCybernetics Society and a Fellow of the I.E.E.E., he has authored over 200 papersin medicine and engineering .Harry Gibbons M .D., M.P .H., Consultant. Dr. Gibb ons has an internationalreputation in the field of public health. It is throug h his professional relationshipswith public health authorities in Mexico that we were able to establish the clinics inwhich IMT is being carried out.The complete Curricula Vitae of ourstaff including m em bers of our Texas andMexico teams are available on request.

IMT and AIDS Privileged and Confidential Page 5


6/13

Project BudgetProject StaffHenry J . Heimlich, M .D.David E. Bresler, Ph.D.Edward A. Patrick, M.D.Harry Gibbons, M.D., M.P.H.To Be Appointed.To Be Appointed

Principal InvestigatorClinical Director, LAMedical Director, H IFConsultantClinical Coordinator, full time(inci.benefits)Project Secretary, full time(inci.benefits)Patient Care CostsClinical Ca re Costs - 1 0 patients @ 25,000 (inci.professional fees)Malaria Donor Costs -1 0 patients @ 3000Medical Supplies/DisposablesCosts for Disposal of Contaminated Materials

Project CostsLaboratory Equipment, Modifications, and Laboratory TestsTraining Technicians*to Safely Handle ContaminantsInformation Co llection, Analysis, and ReportingStaff Travel CostsConsultant CostsAdministrative CostsCommunications, Equipment, Materials, and PostageMiscellaneous Administrative Expense

Base Project Costs10% Contingency

DonatedDonatedDonatedDonated56,25031,250

250,00030,00018,0007 500

50,0005,00020,00025,00015,000

25,0005.000

538,00053.800Total Funds Requested 591,800

* Dr. Heim lich a ccepts no comp ensation from the Heim lich Institute Foundation, Inc.

IMTand AIDS Privileged and Confidential Page 6


7/13

Questions and AnswersWith all of the millions of dollars spent on AIDS research, why have no otherinvestigators yet looked at IMT?

A lbe it Szen t-Gyo rgi once said that disco very con sists of seeing whateveryone else has seen, but thinking what no one else has thought.Investigators have focused on the implications for malaria, and missed theforest for the trees.

Why ha ve n't you approached the National Ca ncer Institute and other governmentalagencies for funding and support?We did initially approach the National Cancer Institute in Bethesda,M aryla nd, for support of a preliminary clinica l study. W e were told that inord er to obtain funding for human clinical trials, we first neede d to conduct aseries of basic research studies utilizing experimental animals.Such studies would require millions of dollars, and more than five years tocom plete . In addition, we believe that the types of viruses utilized tosimu late A IDS in animals are not com parab le to HTV in hum ans, nor is themalaria the same. We question the relevance of such studies to humanAI DS ,and in addition, we do not participate in or support animal research.For us, time is of the essence, and we believe that patient treatment must beinitiated at on ce. The safety of IM T is well docum ented , and if it wereharmful to anyon e, surely the young children involved in the Zaire studywould be most affected.

Why are you conducting this project in Mexico instead of the U.S.?The benign form of malaria we require for treatment is readily available inM exic o. It is currently not present in the United State s.Seco ndly , the cost of treating each subject in a U .S . hospital for 40 dayswould be approximately $100,000, not including professional fees andspecial laboratory tests. Given the preliminary nature of the.treatment, costswo uld not be covered by a health insurance policy . Th us, we are able tocond uct thes e trials in Mexico at significantly low er cost than in the U.S .Finally, our Mexico facility provides the advantages of ready participation

IMT and AIDS Privileged and Confidential -Page 7


8/13

by our Texas medical team, and the availability of a fully equipped U.S.hosp ital in case of em ergenc y. Phy sicians asso ciated with our facilities inboth Te xa s and Mexico have advanced degrees in Public Health, and arewell trained and experienced in treating infectious diseases.. W e are alread y treating American patien ts with Lyme disease and certain

cancers at our facilities in Mexico, and have received all necessary approvalsfrom the Ministry of Health of the Federal Go vernm ent of M exico.

How will the patients be chosen?W e are cu rrently in the process of se lecting ou r uiitial ten HTV positivepatients.

- How will youraise, funds for treatment?Time is of the essence, for the sooner a cure is found, the more lives will besave d. W hile we are considering su bm itting prop osals to various privatefoundations, non-profit c orporations, and A IDS support groups, we areconc erned ab out the length of time required for this proc ess.Instead, we are hoping that a few private benefactors, in concert with theirfriends, will provide the funds w e need to initiate this project. The H eimlichInstitute Fo und ation, Inc., is a 501(c)(3) no n-profit corporation and allcontributions are tax deductible.

What if I have other questions?W e welco me an y other questions regarding this prop osal. For additionalinformation regarding the treatment program, please feel free to contact Dr.Heimlich at 513-221-0002 and Dr. Bresler at 310-455-3634. For otherquestions, please contact Dr. Joanne Ca rson at 310-476 -1235, BruceDavison at 818-783 -0221 , and Lisa Pelikan at 818-783 -0226.

MT and AIDS Privileged and Confidential Page 8


9/13

Appendix AA Brief History of IMT

IM T refers to Indu ced Malaria Therapy wh ich consists of inoculating a patientwith a curable form of malaria (usually Plasmodium vivaxl to cure another diseasethat is otherwise incurab le. It was pioneered by Wag ner-Jauregg who was awardedthe Nobel Prize in 1927 for his discovery that IMT cured neurosyphilis (syphilis ofthe brain).There are four different parasites that cause human malaria, one of which isdifficult to treat; the other three are rapidly curab le with ordinary antimalarialme dicatio n. T o da te, there has not be a single case of malaria related to IM T thathas not been completely cured, so its safety is well documented.Between 1931 and 1965, the US Public Health Service provided numerousphysicians with malaria-infected blood for IMT which resulted in curing tens ofthousand of neurosyphilis patients.In 1 93 1, the N ation al Institutes of Health founded a clinical laboratory inCo lom bia, Sou th Carolina, for the purposes of perfecting m ethod s of the use ofmalaria in the treatment of neurosyphilis and of studying the biology of malaria.From 1941 to its closing in 196 5, it was headed by Martin D . Yo ung , Sc.D ., whoreports that som e 20,000 neurosyphy litic patien ts have bee n inoculated orsubinoculated with strains of malaria maintained and furnished by this laboratory.Dr. Young is at present (1992) Research Professor at the University of Florida.Ga inesv ille. A letter from Dr. Young to Dr. Heim lich dated March 26, 1991 ,confirms his favorable opinion of IMT for Lyme disease.Early penicillin treatment for syphilis after the 1940's prevented new cases ofneurosyphilis from developing, although existing cases were not affected sincepenicillin does not cross the blood-brain barrier. Th us , IM T continued for 20-30years after the development of antibiotics. IMT was discontinued in the UnitedStates in 1965 becau se neurosyphilis had been essentially eradicated. The renownEpsom Laboratories, near London, continued IM T until 1975.It is likely tha t IM T w ill return since, in 1990, mere w ere 50 ,000 n ew cases ofsyphilis reported in the United States, the highest nu m ber in history, even prior toantib iotics . Many of these patients are in late stages of the disease and resistant toeven massive amounts of antibiotics due to decreased host resistance and/or newantibiotic-resistan ce strains of syphilis.

IMT and AIDS -Privileged and Confidential Page 9


10/13

In 1984, Professor Eli Chemin at the Harvard School of Public Health published anhistoric review of IM T. He conclud ed that sev eral related points on the historicallandscape of malariatherapy deserve mention:(.1) On ave rage , malariatherapy was less exp ensiv e and produ ced clinicalimprov em ent m ore frequendy and more rapidly than did the best drugtreatment.(2) The contraindications to malariatherapy, and mere were some, musthave been carefully observed because records of treatment-related deaths orextreme debility are few relative to me mo usand s of patients tre at ed ... It isnot hard to imagine the almost certain fate of the thousand of paretics[neurosyphilitics] who would have sickened horribly and died but formalariatherapy.

Recent research supports the notion that IM T d m enhanc e im mune function. It isthought that malariatherapy's effectiveness may be related in part to its dramaticability to induce production of immune substances, including interleukins andtumor necrosis factor (TNF).In 1990, Dr. Heimlich published the first contemp orary p aper on IM T entidedShould W e Try Malariotherapy for Lyme D isease ? in the New England Journalof Medicine (April 26 ,1 99 0), citing 29 references. To date, there is no otherknow n m ethod for treating patients wim either neurosyp hilis or Lyme disease whodo not respond to antibiotics.The remarkable response to IMT for cancer is evident in the pictures of a patientwith breast cancer treated in our study currentiy underway in China.

IMT and AIDS Privileged and Confidential Page 10


11/13

H E I M U HI N S T I T U T EMHH.K2368 VICTORYPARKWWSUITE4 1

CINCINNATIO H I O4 5 2 6

513-221-0002fax513-221-0003

THE HEIML3CH INSTITUTE FOUNDATION INC.The Hei m i ch I ns t i t ut e Foundat i on, I nc . was or i gi nal l yest abl i shed as t he Dysphagi a Foundat i on, I nc. i n New Yor k,New Yor k i n 1960. The name was changed t o t he Hei m i chI nst i t ut e Foundat i on, I nc. on Sept ember 1, 1982.Pur pose: Sai d cor por at i on i s or gani zed excl us i vel y f orchar i t abl e, educat i onal and sc i ent i f i c pur poses i nc l udi ngthef ol l owi ng: To conduct sc i ent i f i c , cul t ur al and soc i alr esear ch i nt o i ssues of i mpor t ance t o t he medi cal andsc i ent i f i c communi t y and t hei r r el at i onshi p t o soc i alquest i ons; t o i nvest i gat e mat t er s of nat i onal andi nt er nat i onal concer n; t o car r y on r esear ch i nt o and educat i onabout af f l i ct i ons of t he human body; t o pr ovi de educat i on of ,and di ssem nat i on of i nf or mat i on t o , t he publ i c andpr of essi onal s r egar di ng any of t hese mat t er s; and f ur t heri nc l udi ng t he maki ng of di s t r i but i ons , f or t he pur pose ofaccompl i shi ng such pur poses, t o or gani zat i ons t hat qual i f y asexempt or gani zat i ons under Sect i on 501( c) ( 3) of t he I nt er nalRevenue Code of 1954 ( or t he cor r espondi ng pr ovi si on of anyf ut ur e Uni t ed St at es I nt er nal Revenue L aw) , i nc l udi ng thepr ovi s i on, by means of such di s t r i but i ons , of f i nanc i alass i st ance f or medi cal , sur gi cal and hospi t al car e of needyper sons.The Hei m i ch I nst i t ut e Foundat i on pr ov i des f or t he cont i nui ngpur sui t of t he di ver si f i ed wor k of t he wor l d- r enowned sur geon,sc i ent i st , and humani t ar i an, ~ Dr . Henr y J . Hei m i ch, and ourassoci at es and f el l ows. Dr . Hei m i ch i s pr obabl y best knownf or t he Hei m i ch Maneuver , a t echni que t hat has saved t hel i ves of t housands of choki ng and dr owni ng vi ct i ms each year .Nor man Vi ncent Peal e sai d t hat Dr . Hei m i ch i s credi t ed wi t hsavi ng mor e l i ves t han any ot her l i vi ng Amer i can. But t hat i snot a l l . Our cur r ent r esear ch i nc l udes :A. Hei m i ch Maneuver

For Choki ng - saves t housands of l i ves each year .For Dr owni ng - i s t he f i r st st ep f or savi ng dr owni ngvi c t i ms . I t expel s t he wat er f r om t he l ungs. Mout h-t o- mout h i s of l i t t l e val ue when t he l ungs ar e f i l l edwi t h wat er .

e n e f i t i n gH u m a n i t yT h r o u g he a l t ha n dP e a c e

Di ssem nat i on of medi cal knowl edge t o educat e t hepubl i c about t he Hei m i ch Maneuver t hr ough l ect ur es,demonst r at i ons, publ i cat i ons, and ot her medi a.For Ast hma - A new r esear ch pr oj ec t The Hei m i ch Maneuverover comes at t acks wi t hout t he need f or medi cat i on.


12/13

For CPR - A new ' r esear ch pr oj ect accumul at i ng dat a f r omhospi t al s ar ound t he count r y t hat shows t he Hei m i chManeuver t o save t wi ce as many hear t at t ack vi ct i mst han does t he usual CPR.B. Hei m i ch M cro Tr ach - The - s tat e- of - t hear t f or pat i ent s

needi ng oxygen. Pr ovi des rehabi l i t at i on of pat i ent s wi t hemphysema, heart di sease, bl ack l ung, and chr oni cobst r uct i ve pul monar y di sease. Our cur r ent r esear chpr oj ect i s i n cyst i c f i br os i s . I n cys t i c f i br osi s t her ei s a bui l dup of excess mucus i n chi l dr en' s l ungs causi ngdeat h, usual l y i n t hei r t eens o r t went i es , f romsuf f ocat i on due t o dest r uct i on of t he l ungs . The Hei m i chMi cr o Tr ach cl ear s t he l ungs, enabl es easi er br eat hi ng andas si s t s i n act i ve mobi l i t y.C. Lyme Di sease - Thi s debi l i t at i ng di sease i s spr eadi ngt hr ough t he U. S. Mal ar i at her apy st udy and c l i ni calt r eat ment i s bei ng car r i ed out i n Lat i n Amer i ca.D. Cancer - Mal ar i a t r eat ment t o i nduce f ever and st i mul at ei mmune r esponses i n pat i ent s . St udy and c l i ni cal t r i ali s bei ng car r i ed out i n Lat i n Amer i ca and Chi na.Among Dr . Hei m i ch' s ot her not abl e concept s andaccompl i shment s ar e:A. Hei m i ch Oper at i on - Pr ovi des a new esophagus f orvi c t i ms of bi r t h def ec ts - or cancer . I t was t he f i r s tt i me i n hi st or y an or gan had been t ot al l y r epl aced.B. Hei m i ch Val ve f or Chest Dr ai nage - Saves t he l i ves

of per sons wi t h chest i nj ur i es. Saved hundr eds ofl i ves i n t he Vi et nam War , and i t i s now bei ng used i nemer gency r ooms and hospi t al s t hr oughout t he wor l d.C. Hei m i ch Met hod f or Rehabi l i t at i on of Swal l owi ng -r est or es t he abi l i t y t o swal l ow f ood af t er s t r okeor i nj ur y.D. St r ess Rel i ef : The Hei m i ch Met hod - avai l abl e onvi deot ape.E. Dr . Hei m i ch' s Fi r s t Ai d Vi deo f or t r eat ment ofemer genci es.F. Condensed ver si on of Dr . Hei m i ch' s book, Home Gui det o Emer gency Medi cal Si t uat i ons - avai l abl e wi t hcont r i but i on t o t he Hei m i ch I nst i t ut e Foundat i on.G. A Car i ng Wor l d: a l ectur e pr ogr am f or al l t i mes i spr esent ed r egul ar l y at uni ver s i t i es , c l ubs andcor por at e meet i ngs.


13/13

H. Medi cal devi ces - new endot r acheal t ube t hat pr event sscar r i ng and damage t o t he t r achea was i nt r oduced i nJ anuar y 1991.At t he I nst i t ut e, emphas i s i s on us i ng c reat i ve t hi nki ng i nmedi c i ne and l i f e. Each per son can cr eat e wi t hi n t he l i m t sof hi s or her knowl edge and capabi l i t y. W t h t hi s cr eat i vi t y,comes chal l enge, f r ust r at i on and cont r over sy. Dr . Hei m i ch' sf avor i t e phr ase: I f al l of your peer s under st and what youhave done, you ar e not cr eat i ve . But when t he i deas ar epr oven successf ul , despi t e at t empt s t o obst r uct t hemi nevi t abl y t r ut h pr evai l s , and t he j oys and r ewar ds of yourwor k are i nsur mount abl e.The Hei m i ch I nst i t ut e Foundat i on, I nc . i s suppor t edexcl usi vel y t hr ough pr i vat e gr ant s and donat i ons f r om t hepubl i c . We hope you' l l hel p us i n our f ut ur e endeavor s.

heimlich institute's 1992 "immunotherapy for aids" fundraising prospectus

Documents